Logo image of IRTC

IRHYTHM TECHNOLOGIES INC (IRTC) Stock Fundamental Analysis

NASDAQ:IRTC - Nasdaq - US4500561067 - Common Stock - Currency: USD

142.69  +0.25 (+0.18%)

After market: 142.69 0 (0%)

Fundamental Rating

3

Taking everything into account, IRTC scores 3 out of 10 in our fundamental rating. IRTC was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While IRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IRTC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IRTC has reported negative net income.
In the past year IRTC had a positive cash flow from operations.
IRTC had negative earnings in each of the past 5 years.
In the past 5 years IRTC reported 4 times negative operating cash flow.
IRTC Yearly Net Income VS EBIT VS OCF VS FCFIRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.62%, IRTC is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
IRTC has a worse Return On Equity (-113.45%) than 63.49% of its industry peers.
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROIC N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
IRTC Yearly ROA, ROE, ROICIRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

IRTC has a Gross Margin of 69.39%. This is in the better half of the industry: IRTC outperforms 78.31% of its industry peers.
In the last couple of years the Gross Margin of IRTC has declined.
IRTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
IRTC Yearly Profit, Operating, Gross MarginsIRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

5

2. Health

2.1 Basic Checks

IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRTC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IRTC has been increased compared to 5 years ago.
IRTC has a worse debt/assets ratio than last year.
IRTC Yearly Shares OutstandingIRTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRTC Yearly Total Debt VS Total AssetsIRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.17 indicates that IRTC is not in any danger for bankruptcy at the moment.
The Altman-Z score of IRTC (3.17) is better than 72.49% of its industry peers.
IRTC has a Debt/Equity ratio of 7.47. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IRTC (7.47) is worse than 89.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Altman-Z 3.17
ROIC/WACCN/A
WACC8.62%
IRTC Yearly LT Debt VS Equity VS FCFIRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.71 indicates that IRTC has no problem at all paying its short term obligations.
IRTC has a better Current ratio (5.71) than 80.95% of its industry peers.
IRTC has a Quick Ratio of 5.58. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC has a better Quick ratio (5.58) than 83.60% of its industry peers.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.58
IRTC Yearly Current Assets VS Current LiabilitesIRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

IRTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.57%, which is quite impressive.
IRTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.55%.
The Revenue has been growing by 22.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%

3.2 Future

Based on estimates for the next years, IRTC will show a very strong growth in Earnings Per Share. The EPS will grow by 23.74% on average per year.
Based on estimates for the next years, IRTC will show a quite strong growth in Revenue. The Revenue will grow by 17.27% on average per year.
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.74%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRTC Yearly Revenue VS EstimatesIRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
IRTC Yearly EPS VS EstimatesIRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRTC Price Earnings VS Forward Price EarningsIRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRTC Per share dataIRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

IRTC's earnings are expected to grow with 29.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.04%
EPS Next 3Y29.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRHYTHM TECHNOLOGIES INC

NASDAQ:IRTC (5/23/2025, 8:25:54 PM)

After market: 142.69 0 (0%)

142.69

+0.25 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners111.02%
Inst Owner Change2.05%
Ins Owners0.56%
Ins Owner Change1.8%
Market Cap4.56B
Analysts85.26
Price Target137.79 (-3.43%)
Short Float %9.49%
Short Ratio6.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.27%
Min EPS beat(2)4.68%
Max EPS beat(2)103.85%
EPS beat(4)3
Avg EPS beat(4)6.42%
Min EPS beat(4)-115.67%
Max EPS beat(4)103.85%
EPS beat(8)4
Avg EPS beat(8)-15.15%
EPS beat(12)6
Avg EPS beat(12)-8.91%
EPS beat(16)10
Avg EPS beat(16)-0.35%
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)1.42%
Max Revenue beat(2)2%
Revenue beat(4)2
Avg Revenue beat(4)0.32%
Min Revenue beat(4)-1.42%
Max Revenue beat(4)2%
Revenue beat(8)4
Avg Revenue beat(8)0.32%
Revenue beat(12)6
Avg Revenue beat(12)0.04%
Revenue beat(16)10
Avg Revenue beat(16)1.07%
PT rev (1m)2.41%
PT rev (3m)22.07%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)-6.93%
EPS NY rev (3m)1.77%
Revenue NQ rev (1m)1.87%
Revenue NQ rev (3m)0.99%
Revenue NY rev (1m)2.08%
Revenue NY rev (3m)2.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.36
P/FCF N/A
P/OCF 95.83
P/B 52.55
P/tB 53.08
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)1.49
OCFY1.04%
SpS19.38
BVpS2.72
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.39%
FCFM N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 233.65%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.58
Altman-Z 3.17
F-Score6
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)235.33%
Cap/Depr(5y)237.52%
Cap/Sales(3y)7.91%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.74%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.27%
EBIT growth 1Y39.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year143.8%
EBIT Next 3Y45.01%
EBIT Next 5Y33.09%
FCF growth 1Y97.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.62%
OCF growth 3YN/A
OCF growth 5YN/A